Saturday 17 October 2026 Export AHG’s income statement to Excel — free account

Akso Health Group Sponsored ADR

Akso Health Group Sponsored ADR’s revenue for fiscal 2026 (year ended March 2026) was $13.8 million, down 6.40% from fiscal 2025.

1.35 0.00 0.00%

Follow AHG

Alert me

Market cap: $1.2B
P/E: 0.0×
Fwd P/E: 0.0×
Dividend yield: —
F-score: 5/9
Altman Z: 112.75
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 1,150.00

Revenue 20.14

Net Income 15.61

Free Cash Flow (160.20)

Net Debt (11.13)

Current Ratio 1.53

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E 0.00

P/S ratio 1.09

P/B ratio 0.11

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth (100.00%)

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 31.58%

10-year low 10-year high

P/B against its own 10 years 9.60%

10-year low 10-year high

EV/Sales against its own 10 years 41.63%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	0.39	0.39

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	8	85	176	0
Receivables	8	—	13	1
Inventory	2	0	0	0
Other	—	—	—	176
	20	142	196	190

	2023	2024	2025	2026
Payables	—	—	—	—
ST’ Debt	—	—	—	0
Other	0	0	10	4
	12	4	14	9

Compound Annual Growth %

	10y	5y	3y
Sales	1.52%	51.12%	1.62%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	29.15%	59.97%	173.54%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	—	—	14
’25	—	—	—	—	15
’24	—	—	—	—	2
’23	—	—	—	—	13
’22	—	—	—	—	6
’21	—	—	—	—	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	1	—	(13)
’25	—	—	(5)	—	1
’24	—	—	—	—	1
’23	—	—	—	—	(3)
’22	—	—	—	—	(9)
’21	—	—	—	—	10

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	(174)	—	(188)
’25	—	—	(5)	—	1
’24	—	—	0	—	1
’23	(2)	—	(1)	—	(3)
’22	(9)	—	1	—	(9)
’21	—	—	—	—	10

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	—	—	(0.03)
’25	—	—	—	—	(0.48)
’24	—	—	—	—	—
’23	—	—	—	—	(0.02)
’22	—	—	—	—	(0.28)
’21	—	—	—	—	(0.71)

Fiscal quarters ending in the months shown.

value withheld pending a data check

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	32.40	5.61	1.20	0.77	1.23	0.20	0.25	0.60	0.83	0.68	Analyst estimates 2027–2029 Powerpack
	High	51.00	40.56	12.30	7.44	22.39	2.34	2.11	2.90	2.10	2.50
People
People	Employees	295	400	552	182	113	42	12	9	9	12
	Revenue/emp, $m	0.08	0.27	0.11	0.04	0.02	0.14	1.10	0.27	1.64	1.15
Income, $m
Income, $m	Revenue	23	107	61	7	2	6	13	2	15	14
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	10.09	9.63	5.06	(1.90)	(0.08)
	EBT	10	77	7	(47)	(31)	(4)	(13)	(9)	(166)	(21)
	EBT margin, %	44.04	71.36	12.07	(677.90)	(1,770.43)	(66.81)	(99.13)	(376.58)	(1,125.14)	(149.69)
	Net income	9	66	6	(47)	(32)	(4)	(13)	(9)	(135)	(19)
	Depreciation	0	0	0	0	0	0	—	—	2	2
Per share, $
Per share, $	Revenue	1.62	7.15	3.78	0.43	0.11	0.30	0.58	0.05	0.05	0.02
	Earnings	0.61	4.38	0.33	(4.38)	(0.71)	(0.28)	(0.02)	(0.07)	(0.48)	(0.03)
	Cash flow	0.58	5.85	(0.11)	(3.59)	0.62	(0.43)	(0.14)	0.03	0.00	(0.02)
	Capex	(0.02)	(0.03)	(0.06)	(0.01)	0.00	0.00	0.00	0.00	0.00	(0.24)
	Free cash flow	0.56	5.82	(0.16)	(3.60)	0.62	(0.43)	(0.14)	0.03	0.00	(0.26)
	Book value	1.67	9.34	7.79	2.96	1.06	0.62	0.39	2.93	0.70	0.25
	Shares, m	14	15	16	16	16	20	23	47	285	723
Valuation, ×
Valuation, ×	P/E	7.48	7.88	27.83	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	4.79	2.65	1.32	2.56	3.43	0.30	0.92	0.95	1.84
	P/B	4.99	3.67	1.29	0.20	1.66	2.24	0.67	3.48	0.10	0.19
	EV/Sales	0.00	3.56	2.04	1.69	3.05	3.28	0.96	1.49	(2.36)	2.51
	EV/FCF	4.94	3.57	1.37	0.62	0.81	0.65	(1.37)	(2.12)	(3.52)	(0.32)
Cash, $m
Cash, $m	Operating cash flow	8	88	(2)	(58)	10	(9)	(3)	1	1	(13)
	Capex	0	0	(1)	0	—	0	—	—	0	(176)
	Free cash flow	8	87	(3)	(58)	10	(9)	(3)	1	1	(188)
Balance, $m
Balance, $m	Working capital	23	139	71	40	16	12	9	138	182	181
	Total debt	—	—	20	21	10	—	—	—	—	0
	Net debt	(19)	(133)	(37)	14	(5)	(18)	(8)	(85)	(176)	0
	Shareholders’ equity	24	140	127	48	17	12	9	138	199	181
Returns, %
Returns, %	ROA	60.40	68.11	3.28	(56.12)	(62.10)	(35.67)	(3.27)	(11.64)	(75.62)	(9.23)
	ROIC	145.03	639.06	3.57	(48.36)	(159.07)	0.00	(974.52)	(10.14)	(453.47)	(7.14)
	ROE	45.69	80.08	4.15	(81.55)	(106.55)	(114.02)	(12.87)	(12.85)	(79.97)	(9.83)

Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Sep 2019

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
COR Cencora, Inc.	$65.2B	25.2×	14.5×	+5.07% (above 0%: growing)	+11.27% (above 0%: growing)	+3,385.25% (above 0%: growing)	4.26%	1.32%	Compare
CAH Cardinal Health, Inc.	$58.8B	35.0×	23.3×	+5.84% (above 0%: growing)	+68.32% (above 0%: growing)	+10.87% (above 0%: growing)	4.02%	1.14%	Compare
HSIC Henry Schein, Inc.	$9.7B	25.0×	18.5×	+6.73% (above 0%: growing)	+16.90% (above 0%: growing)	+140.91% (above 0%: growing)	31.84%	4.95%	Compare
AHG Akso Health Group Sponsored ADR	$1.2B	— (loss-making)	— (loss-making)	+263.89% (above 0%: growing)	n/m	−12,975.04% (below 0%: shrinking)	0.00%	0.00%
FOCL FocalTherics	$154.8M	— (loss-making)	— (loss-making)	+38.85% (above 0%: growing)	n/m	+21.49% (above 0%: growing)	55.59%	(60.83%)	Compare
COSM Cosmos Health Inc.	$33.9M	— (loss-making)	25.1×	+28.76% (above 0%: growing)	n/m	+9.39% (above 0%: growing)	7.96%	(15.41%)	Compare
ACH Accendra Health, Inc.	$20.1M	— (loss-making)	— (loss-making)	−10.07% (below 0%: shrinking)	n/m	−1,624.82% (below 0%: shrinking)	42.95%	(5.73%)	Compare
HKPD Cellyan Biotechnology Co., Ltd	$17.1M	—	—	—	—	−90.45% (below 0%: shrinking)	—	—	Compare
YI 111, Inc. Sponsored ADR	$16.0M	— (loss-making)	— (loss-making)	−29.61% (below 0%: shrinking)	n/m	−185.70% (below 0%: shrinking)	5.33%	(0.85%)	Compare
Median of peers	$94.3M	25.2×	20.9×	+5.84%	+16.90%	+10.13%	7.96%	(0.85%)

All 11 Medical Distribution stocks →